Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NANO-X IMAGING LTD.

(NNOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanox to Announce Second Quarter 2021 Financial and Operating Results on Tuesday, August 10, 2021

07/27/2021 | 08:01am EDT

NEVE ILAN, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its second quarter 2021 financial and operating results for the period ended June 30, 2021 on Tuesday, August 10, 2021 prior to the start of trading. Management will host a conference call and webcast at 8:30am ET on that day.

Conference call and webcast details
Tuesday, August 10, 2021 @ 8:30am ET
Investor domestic dial-in:   855-327-6837
Investor international dial-in:   631-891-4304
Conference ID: 10015901
Webcast link: http://public.viavid.com/index.php?id=146006

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; and Nanox's ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.

Contact:

Itzhak Maayan
Nanox Imaging
IR@nanox.vision

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com


Primary Logo


ę GlobeNewswire 2021
All news about NANO-X IMAGING LTD.
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-..
PR
08/24SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-..
PR
08/19SECTOR UPDATE : Health Care Stocks Higher Ahead of Thursday Close
MT
08/19SECTOR UPDATE : Health Care Stocks Advancing This Afternoon But Biotech Struggle
MT
08/19NANO X IMAGING : Shares Fall After FDA Places Nanox.ARC Device Application on Hold
MT
08/12Nanox to Host Business Update Video Presentation
GL
08/10NANO X IMAGING : to Acquire Zebra Medical Vision; Signs Binding Letter of Intent to Acquir..
MT
08/10NANO X IMAGING : Posts Wider Q2 Loss
MT
08/10NANO X IMAGING : Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vis..
PU
08/10NANO X IMAGING : Earnings Flash (NNOX) NANO-X IMAGING Reports Q2 Loss $-0.18, vs. Street E..
MT
More news
Analyst Recommendations on NANO-X IMAGING LTD.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -54,6 M - -
Net cash 2021 193 M - -
P/E ratio 2021 -19,9x
Yield 2021 -
Capitalization 1 089 M 1 089 M -
EV / Sales 2021 -
EV / Sales 2022 89,2x
Nbr of Employees 50
Free-Float 77,1%
Chart NANO-X IMAGING LTD.
Duration : Period :
Nano-X Imaging Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANO-X IMAGING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 22,76 $
Average target price 42,25 $
Spread / Average Target 85,6%
EPS Revisions
Managers and Directors
Ran Poliakine Chairman & Chief Executive Officer
Itzhak Maayan Chief Financial Officer
Ofir Koren Chief Technology Officer
Uri Shimon Vice President-Information Systems & Technology
James Dara Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANO-X IMAGING LTD.-50.15%1 089
SONOSCAPE MEDICAL CORP.29.62%2 084
BEIJING WANDONG MEDICAL TECHNOLOGY CO., LTD.88.24%1 579
RAY CO., LTD.18.76%355
VIEWORKS CO., LTD.35.26%326
SDI GROUP PLC69.04%274